This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $289.64, marking a +0.7% move from the previous day.
AbbVie's (ABBV) Rinvoq Gets FDA Nod for Ulcerative Colitis
by Zacks Equity Research
FDA approves AbbVie's (ABBV) Rinvoq for the treatment of moderate-to-severe ulcerative colitis in adults. This is the fourth indication for Rinvoq in the United States.
Incyte's (INCY) Going Gets Tough Due to Pipeline Setbacks
by Zacks Equity Research
The recent pipeline setbacks will weigh on Incyte's (INCY) growth trajectory and jeopardize its plans to diversify its revenue base.
Should iShares MSCI USA Min Vol Factor ETF (USMV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for USMV
Nektar (NKTR) Plunges on Bempeg's Melanoma Study Failure
by Zacks Equity Research
Nektar (NKTR) and Bristol-Myers announce that the bempeg plus Opdivo regimen fails to meet the primary endpoint of progression-free survival and objective response rate in a late-stage melanoma study.
If You Invested $1000 in Eli Lilly 10 Years Ago, This Is How Much You'd Have Now
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $269, marking a +1.01% move from the previous day.
The Zacks Analyst Blog Highlights : Eli Lilly, Nike, Micron Technology, Bayer Aktiengesellschaft, and Valero Energy
by Zacks Equity Research
Eli Lilly, Nike, Micron Technology, Bayer Aktiengesellschaft, and Valero Energy are included in today's analyst blog.
Top Analyst Reports for Eli Lilly, NIKE & Micron Technology
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), NIKE, Inc. (NKE) and Micron Technology, Inc. (MU).
Mirati (MRTX) Focuses on Seeking Nod for KRAS Drug Adagrasib
by Zacks Equity Research
Mirati's (MRTX) regulatory filing to the FDA for adagrasib in second-line NSCLC gets a longer-than-expected review period. MRTX is progressing well with the pipeline development for other candidates.
AbbVie's (ABBV) Qulipta Meets Chronic Migraine Study Endpoints
by Zacks Equity Research
AbbVie's (ABBV) new oral anti-CGRP drug, Qulipta, demonstrates potential to reduce monthly migraine days in adults with chronic migraine in a phase III study.
Eli Lilly (LLY) Stock Moves -0.65%: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $259.93, moving -0.65% from the previous trading session.
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
WHO Recommends Merck (MRK) Oral Pill for Certain COVID Patients
by Ekta Bagri
Merck's (MRK) and Ridgeback Biotherapeutics' oral antiviral drug molnupiravir has been included in the treatment guidelines for COVID-19 by WHO.
Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $254.17 in the latest trading session, marking a +1.87% move from the prior day.
Nektar (NKTR) Q4 Earnings Top, Three Bempeg Filings Due in 2022
by Zacks Equity Research
Nektar (NKTR) reports mixed fourth-quarter 2021 results. The company remains on track to report top-line data from three registrational studies on bempegaldesleukin in the first half of 2022.
ImmunoGen (IMGN) Q4 Earnings and Sales Outpace Estimates
by Zacks Equity Research
ImmunoGen (IMGN) reports a narrower-than-expected loss for fourth-quarter 2021. It also beats revenue estimates. Post the announcement, the share price rises.
Radius (RDUS) Q4 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Radius (RDUS) beats on earnings and sales in the fourth quarter. The guidance is disappointing.
United Therapeutics (UTHR) Q4 Earnings & Sales Miss, Stock Down
by Zacks Equity Research
United Therapeutics (UTHR) fourth-quarter earnings and sales miss estimates. Higher sales of Tyvaso and Unituxin mainly drive the top line in the quarter, offset by lower sales of other drugs.
Pharma Stock Roundup: GSK, SNY Face Pipeline Setbacks, AZN Cancer Study Meets Goals
by Kinjel Shah
Glaxo (GSK) and Sanofi (SNY) announce pipeline setbacks. AstraZeneca's (AZN) HER2-low metastatic breast cancer study on Enhertu succeeds.
Pharma Stock Roundup: EU Approval to PFE, AZN Products, FDA Nod to LLY New COVID Drug
by Kinjel Shah
FDA grants EUA to Eli Lilly's (LLY) new COVID antibody-drug, bebtelovimab. AstraZeneca's (AZN) Saphnelo and Pfizer's (PFE) Ngenla (somatrogon) and Apexxnar vaccine get approval in Europe
GSK vs. LLY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
GSK vs. LLY: Which Stock Is the Better Value Option?
ImmunoGen (IMGN) Up on Licensing Deal With Lilly Worth $1.7 B
by Zacks Equity Research
ImmunoGen (IMGN) inks a licensing agreement with Eli Lilly, granting the latter rights to develop and commercialize ADCs directed toward targets selected by Lilly. Stock up.
Biohaven (BHVN) Migraine Drug Meets Study Goals in China
by Zacks Equity Research
Biohaven (BHVN) and partner Pfizer announce positive top-line results from a phase III study on rimegepant for the acute treatment of migraine. The study meets the co-primary endpoints.
ProQR (PRQR) Plunges as Lead Drug Fails in Phase II/III Study
by Zacks Equity Research
ProQR (PRQR) lead candidate sepofarsen did not meet primary and secondary goals in phase II/III study.